233 related articles for article (PubMed ID: 23266085)
1. Histone lysine demethylases in breast cancer.
Paolicchi E; Crea F; Farrar WL; Green JE; Danesi R
Crit Rev Oncol Hematol; 2013 May; 86(2):97-103. PubMed ID: 23266085
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
5. [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
Fu X; Yu G; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1822-1831. PubMed ID: 36651250
[TBL] [Abstract][Full Text] [Related]
6. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
[TBL] [Abstract][Full Text] [Related]
7. Jumonji histone demethylases as emerging therapeutic targets.
Park SY; Park JW; Chun YS
Pharmacol Res; 2016 Mar; 105():146-51. PubMed ID: 26816087
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
Denis H; Van Grembergen O; Delatte B; Dedeurwaerder S; Putmans P; Calonne E; Rothé F; Sotiriou C; Fuks F; Deplus R
Mol Biosyst; 2016 Feb; 12(2):404-13. PubMed ID: 26621457
[TBL] [Abstract][Full Text] [Related]
9. KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
Blair LP; Liu Z; Labitigan RL; Wu L; Zheng D; Xia Z; Pearson EL; Nazeer FI; Cao J; Lang SM; Rines RJ; Mackintosh SG; Moore CL; Li W; Tian B; Tackett AJ; Yan Q
Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of histone lysine demethylases in prostate cancer.
Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.
Liu H; Liu L; Holowatyj A; Jiang Y; Yang ZQ
Mol Carcinog; 2016 May; 55(5):977-90. PubMed ID: 26207617
[TBL] [Abstract][Full Text] [Related]
12. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
He X; Zhang H; Zhang Y; Ye Y; Wang S; Bai R; Xie T; Ye XY
Eur J Med Chem; 2022 Mar; 231():114143. PubMed ID: 35101649
[TBL] [Abstract][Full Text] [Related]
13. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
[TBL] [Abstract][Full Text] [Related]
14. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Lee SW; Park DY; Kim MY; Kang C
Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
16. JmjC Family of Histone Demethylases Form Nuclear Condensates.
Vicioso-Mantis M; Aguirre S; Martínez-Balbás MA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887017
[TBL] [Abstract][Full Text] [Related]
17. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
[TBL] [Abstract][Full Text] [Related]
18. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li CY; Wang W; Leung CH; Yang GJ; Chen J
Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
[TBL] [Abstract][Full Text] [Related]
19. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Hinohara K; Wu HJ; Vigneau S; McDonald TO; Igarashi KJ; Yamamoto KN; Madsen T; Fassl A; Egri SB; Papanastasiou M; Ding L; Peluffo G; Cohen O; Kales SC; Lal-Nag M; Rai G; Maloney DJ; Jadhav A; Simeonov A; Wagle N; Brown M; Meissner A; Sicinski P; Jaffe JD; Jeselsohn R; Gimelbrant AA; Michor F; Polyak K
Cancer Cell; 2018 Dec; 34(6):939-953.e9. PubMed ID: 30472020
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs).
Tarhonskaya H; Tumber A; Kawamura A; Schofield CJ
Curr Protoc Pharmacol; 2018 Mar; 80(1):3.15.1-3.15.12. PubMed ID: 30040204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
